Prostate Cancer - Results from #21740

Very-high-risk localized prostate cancer: Definition and outcomes - Abstract November 29, 2013

Next-generation therapy for residual prostate cancer - Abstract November 29, 2013

Monotherapeutic high-dose-rate brachytherapy for prostate cancer: A dose reduction trial - Abstract November 29, 2013

Evaluation of treatment plan quality of IMRT and VMAT with and without flattening filter using Pareto optimal fronts - Abstract November 29, 2013

The hormonal treatment in prostate cancer - Abstract November 29, 2013

Long-term cancer control after radical prostatectomy and bilateral pelvic lymph node dissection for pT3bN0M0 prostate cancer in the prostate-specific antigen era - Abstract November 29, 2013

Reference values for the CAVIPRES-30 Questionnaire, a global questionnaire on the health-related quality of life of patients with prostate cancer - Abstract November 29, 2013

Outcomes following iodine-125 prostate brachytherapy with or without neoadjuvant androgen deprivation - Abstract November 28, 2013

Percentage of cancer involvement in positive cores can predict unfavorable disease in men with low-risk prostate cancer but eligible for the Prostate Cancer International: Active Surveillance criteria - Abstract November 28, 2013

Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer: Analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry - Abstract November 28, 2013

African American men's and women's perceptions of clinical trials research: Focusing on prostate cancer among a high-risk population in the South - Abstract November 28, 2013

Metastatic castration-resistant prostate cancer: Critical review of enzalutamide - Abstract November 27, 2013

Clinical benefits of non-taxane chemotherapies in unselected symptomatic metastatic castration-resistant prostate cancer patients after docetaxel: The Getug P02 study - Abstract November 27, 2013

Clinical use of novel urine and blood based prostate cancer biomarkers: A review - Abstract November 27, 2013

A new model consists of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of prostate cancer - Abstract November 27, 2013

Potency preservation following stereotactic body radiation therapy for prostate cancer - Abstract November 27, 2013

Metabolic atrophy and 3T 1H - MR spectroscopy correlation after radiation therapy for prostate cancer - Abstract November 27, 2013

Dietary and serum lycopene levels in prostate cancer patients undergoing intensity-modulated radiation therapy - Abstract November 27, 2013

High-intensity focused ultrasound treatment of prostate cancer - Abstract November 27, 2013

Effect of endorectal balloon positioning errors on target deformation and dosimetric quality during prostate SBRT - Abstract November 27, 2013

Page 1088 of 1436